WASHINGTON & CARLSBAD, Calif. & BOSTON--(BUSINESS WIRE)--Early stage biotech partnering and source funding are the subjects of a keynote panel and are topics on the program at BioPharm America™ 2013, September 17–19 at the Westin Boston Waterfront in Boston, MA.
The keynote panel on Wednesday, September 18, entitled “Who will be funding early stage biotech in the future?” is moderated by well-known industry analyst Luke Timmerman, VP of Life Science Initiatives, Xconomy. Panelists include Bruce Booth, Partner at Atlas Venture; Alexis Borisy, Partner at Third Rock Ventures; Jens Eckstein, President of SR One; Dennis Purcell, Senior Managing Partner at Aisling Capital; and Gregory C. Simon, CEO of Poliwogg Holdings, Inc.
“This topic is extremely timely. The recession is still a not too distant memory in investors’ minds, but the new optimism is real, and recent IPO activity is fueling the interest of VCs,” said Timmerman. “This panel will get the straight talk directly from investors on what is really going on in the markets, and if past is prologue in shaping the future of biotech investing.”
“Early stage biotech research is inherently risky, and for venture firms syndication used to be the way to mitigate this risk,” said Borisy. “Today there are fewer VC firms actively investing in early stage companies. This group is sometimes going it alone through the company formation phase before looking to syndicate, taking a much more hands on approach to company building and assuming greater risk with the prospect of greater reward. There are pros and cons to this approach, and I look forward to the discussion on this topic at BioPharm America.”
“It is time to turn the valley of death into the bridge of life by expanding the pool of investors in early stage health companies. The jobs act allows us for the first time to inform the public about private offerings and attract millions of new investors who want to invest in things they care about,” said Simon. “By translating projects so the public can understand their potential benefit we can unleash the tremendous amount of untapped potential for early stage life science companies.”
Other program offerings that touch upon biotech partnering include the panel “Why can’t big pharma invest in my company?” and “Partnering: Thinking beyond the deal,” a roundtable discussion.
BioPharm America is organized by EBD Group, the leading partnering firm for the life science industry, in collaboration with the Massachusetts Biotechnology Council (MassBio). One-to-one networking at BioPharm America™ is powered by partneringONE®, the leading conference networking solution for the life sciences.
Registration information is available at http://www.ebdgroup.com/bpa/registration/index.php. MassBio members receive an additional USD 200 discount by adding the code ‘MassBio’ in the comments field of the online registration form.
About BioPharm America 2013
BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.
Additional links and information:
Notes to Editors:
Entry to BioPharm America 2013 is free to members of the press, including full access to the partnering system, sessions, press conferences, workshops, and pre-arranged partnering meetings. Visit the BioPharm America conference website at http://www.ebdgroup.com/bpa/registration/press_reg.php for press registration details.
Online Press Kit service for BioPharm America™ 2013, is offering services to enhance your public relations efforts.
MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation's oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
- Partnering for Global Impact®, an inspirational partnering conference providing an innovative forum to partner, identify and generate social and philanthropic investment and funding opportunities
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.